These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR. BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881 [Abstract] [Full Text] [Related]
3. Aromatase inhibitors in the treatment of early and advanced breast cancer. Joensuu H, Ejlertsen B, Lønning PE, Rutqvist LE. Acta Oncol; 2005 Dec; 44(1):23-31. PubMed ID: 15848903 [Abstract] [Full Text] [Related]
5. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole. Karagöz B, Ayata A, Bilgi O, Uzun G, Unal M, Kandemir EG, Ozgün A, Türken O. Onkologie; 2009 Jul; 32(7):421-3. PubMed ID: 19556821 [Abstract] [Full Text] [Related]
6. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M. J Clin Oncol; 2008 Apr 01; 26(10):1671-6. PubMed ID: 18375896 [Abstract] [Full Text] [Related]
8. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen. Carpenter R. Eur J Surg Oncol; 2008 Jul 01; 34(7):746-55. PubMed ID: 18296017 [Abstract] [Full Text] [Related]
10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550 [Abstract] [Full Text] [Related]
11. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Yu KD, Zhou Y, Liu GY, Li B, He PQ, Zhang HW, Lou LH, Wang XJ, Wang S, Tang JH, Liu YH, Wang X, Jiang ZF, Ma LW, Gu L, Cao MZ, Zhang QY, Wang SM, Su FX, Zheng H, Li HY, Tang LL, Sun SR, Liu JP, Shao ZM, Shen ZZ. Breast Cancer Res Treat; 2012 Jul 01; 134(1):307-13. PubMed ID: 22527106 [Abstract] [Full Text] [Related]
12. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Baigent A, Lashen H. Fertil Steril; 2011 Jun 01; 95(7):2429.e5-7. PubMed ID: 21496808 [Abstract] [Full Text] [Related]